Follow The Filings

TLRY Tilray Brands Inc.

Health Care, filed as Tilray Brands, Inc (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner

Who owns TLRY

Sorted by value, long equity only, as of 2026 Q3.

History
Kentucky Trust Co., Kentucky Trust <0.01% Hold 25 — History

1 current, options excluded

Insider trades

Open-market buys and sales by TLRY's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TLRY insider trades
  • $69K bought by 3 insiders
  • $233K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Mitchell Gendel Global General Counsel
    Buy
    $11K 2,500 shares at $4.43 +2% to stake
    Traded Aug 6 Filed Aug 7
    ↗
  2. Carl A Merton CFO
    Buy
    $46K 10,000 shares at $4.62 +7.7% to stake
    Traded Aug 4 Filed Aug 4
    ↗
  3. Denise M Faltischek Chief Strategy Officer
    Buy
    $12K 2,500 shares at $4.78 +1.8% to stake
    Traded Aug 3 Filed Aug 4
    ↗
  4. David G. Hopkinson Director
    Sale
    $233K 33,556 shares at $6.94 100% of stake
    Traded Apr 21 Filed Apr 22
    ↗

Also filed in the last 12 months, not counted as buying or selling: 23 option exercises and 19 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
10-Q FORM 10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 3.02 Filing Doc
8-K 3.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K FORM 10-K Filing Doc
8-K 3.02 Filing Doc
8-K 3.02 Filing Doc
424B7 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 3.02 Filing Doc
8-K 1.01,9.01 Filing Doc
424B5 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 1.01,2.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 3.03,5.03,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Revenue $627.12M $788.94M $821.31M $915.45M
Gross profit $146.96M $223.35M $240.57M $260.44M
Gross margin * 23.4% 28.3% 29.3% 28.4%
Net income -$1.45B -$0.245B -$2.19B -$0.121B
Net margin * -231.6% -31.1% -266.3% -13.3%

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $773.03M $677.71M $688.63M $792.13M
Total non-current assets * $3.53B $3.54B $1.39B $1.54B
Total assets $4.31B $4.22B $2.07B $2.33B
Total current liabilities $432.98M $299.17M $280.3M $358.38M
Total non-current liabilities * $544.34M $479.32M $304.45M $374.76M
Total equity $3.32B $3.44B $1.51B $1.61B

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations $7.91M -$30.9M -$94.6M -$69.14M
Cash from investing -$285.11M $128.35M -$46.72M -$55.8M
Cash from financing $70.16M -$75.19M $133.51M $130.99M
Net change in cash -$209.28M $21.71M -$6.67M $7.68M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.